目的 探讨芪倍合剂联合美沙拉嗪肠溶片治疗活动期溃疡性结肠炎的临床疗效。方法 选取2019年1月-2019年6月于新乡医学院第一附属医院门诊及住院治疗的96例活动期溃疡性结肠炎患者作为研究对象，将所有溃疡性结肠炎患者随机分为对照组和治疗组，每组各48例。对照组口服美沙拉嗪肠溶片，1 g/次，4次/d；治疗组在对照组治疗的基础上口服芪倍合剂，50 mL/次，3次/d。两组疗程均为8周。观察两组患者的临床疗效，比较两组的临床症状缓解时间、血清白细胞介素-33（IL-33）、可溶性血清基质裂解素（sST2）水平和复发率情况。结果 治疗后，对照组、治疗组的临床总有效率分别为79.17%、93.75%，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组血便消失平均时间、腹泻次数至少降低50%所需时间与对照组相比均显著缩短，差异均具有统计学意义（P<0.05）。治疗2、4、8周后，两组患者血清IL-33、sST2水平同治疗前相比均显著下降（P<0.05）；且治疗2、4、8周后，治疗组患者血清IL-33、sST2水平均显著低于同期对照组（P<0.05），差异均具有统计学意义（P<0.05）。随访3个月，对照组和治疗组患者的复发率分别为30.56%、9.30%，差异具有统计学意义（P<0.05）。结论 芪倍合剂联合美沙拉嗪肠溶片治疗活动期溃疡性结肠炎的临床疗效较好，能迅速改善患者血便、腹泻症状，降低机体的炎症因子水平，有着良好的临床应用价值。

Objective To explore the clinical efficacy of Qibei Mixture combined with Mesalazine Enteric-coated Tablet in treatment of active ulcerative colitis. Methods Patients (96 cases) with active ulcerative colitis in outpatient and inpatient of the First Affiliated Hospital of Xinxiang Medical University from January 2019 to June 2019 were randomly divided into control and treatment groups, and each group had 48 cases. Patients in the control group were po administered with Mesalazine Enteric-coated Tablets, 1 g/time, four times daily. Patients in the treatment group were po administered with Qibei Mixture on the basis of the control group, 50 mL/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and the remission time of clinical symptoms, the serum levels of IL-33 and sST2, and the relapse rate in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 79.17% and 93.75%, respectively, and there was difference between two groups (P<0.05). After treatment, the average time of bloody stool disappearance and the frequency of diarrhea decreased at least 50% than before treatment in the treatment group were significantly lower than those in the control group (P<0.05). After treatment for 2, 4, and 8 weeks, the serum levels of IL-33 and sST2 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the serum levels of IL-33 and sST2 in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Follow up for 3 months, the clinical efficacies in the control and treatment groups were 30.56% and 9.30%, respectively, and there was difference between two groups (P<0.05). Conclusion Qibei Mixture combined with Mesalazine Enteric-coated Tablet has clinical curative effect in treatment of active ulcerative colitis, can rapidly improve the symptoms of bloody stool and diarrhea, reduce the levels of IL-33 and ST2, and has a good clinical application value.

R975

河南省科技攻关项目（192102310315）